🔊CEOInterviews

James Foster on M&A strategy

From Charles River Laboratories International Inc ($CRL) Q4 2025 Earnings Call · · Castify Earnings Call

“In January, we announced the planned acquisitions of the assets of KF Cambodia and Pathquest. Both of these acquisitions are squarely aligned with our core competencies and are the result of lengthy successful partnerships. KF, the acquisition of which has already closed, has been our longtime NHP supplier in Cambodia and will further strengthen and secure our DSA supply chain.”

James Foster
Chief Executive Officer, President & Chairman, Charles River Lbrtrs ntrntl Inc
Policy Impact M&A strategysupply chain securityNHP sourcing

On , James Foster, Chief Executive Officer, President & Chairman at Charles River Lbrtrs ntrntl Inc, spoke about M&A strategy during Charles River Laboratories International Inc ($CRL) Q4 2025 Earnings Call on Castify Earnings Call.

Charles River Laboratories International Inc ($CRL) Q4 2025 Earnings Call
Watch on YouTube at 4:58
Charles River Laboratories International Inc ($CRL) Q4 2025 Earnings Call
Castify Earnings Call
Watch on YouTube at 4:58
James Foster

About James Foster

Chief Executive Officer, President & Chairman · Charles River Lbrtrs ntrntl Inc

James Foster, Chairman, President, and CEO of Charles River Laboratories, marked his 50th anniversary with the company in April 2026 by ringing the opening bell at the New York Stock Exchange. He is set to retire as CEO in May 2026 but will remain on the board of directors. In interviews, Foster described his tenure as a "great run" and said he is most proud of the company's scientific depth, portfolio sophistication, and its "familial" and "team oriented" culture. He stated that Charles River works on over 80% of drugs approved by the FDA in the last five years. On the company's Q4 2025 earnings call in February 2026, Foster reported that 2025 financial results were at the upper ends of previously provided revenue and non-GAAP earnings per share ranges. He noted a stabilization of the biopharma demand environment and "substantial improvements" in Discovery and Safety Assessment (DSA) net bookings. Foster announced the planned acquisitions of KF Cambodia and Pathquest, stating they align with core competencies and are expected to generate operating margin improvement through cost savings on non-human primate (NHP) sourcing. He expressed cautious optimism that favorable DSA demand trends will continue in 2026, with a return to organic revenue growth expected in the second half of the year.

Profile compiled from James Foster's verified public interviews and appearances. See all quotes & transcripts →

More from James Foster Charles River Laboratories (CRL) Full Transcript Explore All Executives